P355: A structured care pathway improves quality of care for acute severe ulcerative colitisECCO '17 Barcelona
2017
P356: Treatment with anakinra induces T cell production of IL22 and GI mucosal healing in an IL-10RA mutation patientECCO '17 Barcelona
2017
P357: A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel diseaseECCO '17 Barcelona
2017
P358: Efficacy of golimumab for the treatment of ulcerative colitis patients in clinical practice: a retrospective cohort studyECCO '17 Barcelona
2017
P359: Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countriesECCO '17 Barcelona
2017
P360: Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patientsECCO '17 Barcelona
2017
P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remissionECCO '17 Barcelona
2017
P362: Magnetic resonance healing predicts long-term outcomes in patients with Crohn's diseaseECCO '17 Barcelona
2017
P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT studyECCO '17 Barcelona
2017
P364: A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P365: Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practiceECCO '17 Barcelona
2017
P366: The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experienceECCO '17 Barcelona
2017
P367: The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-makingECCO '17 Barcelona
2017
P369: Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteersECCO '17 Barcelona
2017
P370: A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel diseaseECCO '17 Barcelona
2017
P371: Healthcare maintenance in inflammatory bowel disease patients: need for a top down approachECCO '17 Barcelona
2017
P372: The long term course of patients undergoing ileal pouch-anal anastomosis for ulcerative colitisECCO '17 Barcelona
2017